Kinase Target Engagement

The NanoBRET® Target Engagement (TE) Intracellular Kinase Assays provide a way to quantitatively measure specific kinase-inhibitor interactions in live cells using Bioluminescence Resonance Energy Transfer (BRET). The assay measures the apparent cellular affinity of test compounds bound by competitive displacement of a cell-permeable fluorescent NanoBRET® tracer, reversibly bound to a kinase-NanoLuc® luciferase fusion in cells.

NanoBRET® Kinase Target Engagement Assays

  • Measure Kinase Target Engagement in Live Cells: Quantify compound affinity & fractional occupancy for multiple types of kinase inhibitors (I-IV).
  • Assays for over 340 Kinases: Ready-to-use assays span the kinome, readily enabling selectivity analysis.
  • Use Full-Length Kinase: Assays use full-length wild-type kinases. Select mutant kinase or domain-specific kinase assays are available.
  • Multi-Well Plate Format: Simple assay method is scalable from 96-well to 384-well or beyond.
  • Assess Residence Time: Determine duration of test compound binding to target kinase in live cells.

What You Need to Perform a NanoBRET® TE Assay

Diagram illustrating three key components of a kinase assay workflow.
Promega supplies the individual Kinase-NanoLuc® fusion vector and the appropriate NanoBRET® TE Kinase Assay. For a given kinase, the recommended NanoBRET® TE Kinase assay and application note can be found in the Kinase Target Engagement Selection Table. If you prefer to use your own cells, you will need to provide the cells and cell culture reagents. Alternatively, streamline your workflow with TransfectNow™ HEK293 Cells, eliminating the need for pre-experiment cell culturing.

The tracers and substrate/inhibitor combinations are also available as standalone products.

340 以上のキナーゼで利用可能なアッセイ

すべてのキナーゼを見るSee All Kinase Assays

Filter By


Kinase TE Products

Shop All Kinase Target Engagement Products

Showing 15 of 15 Products

How NanoBRET® Kinase Target Engagement Assays Work

A Kinase-NanoLuc® fusion vector is introduced by transfection into mammalian cells and allowed to express. As NanoLuc® luciferase is extremely bright, only low expression of the kinase-NanoLuc® fusion protein is needed.

In the NanoBRET® TE Kinase Assay, a cell-permeable fluorescent NanoBRET® tracer, a NanoLuc® substrate, and the Extracellular NanoLuc® Inhibitor are supplied. Addition of these to cells expressing the kinase-NanoLuc® fusion allows a strong BRET signal to be achieved between the kinase-NanoLuc® protein and NanoBRET® tracer. The extracellular NanoLuc® inhibitor ensures that the BRET signal achieved is from live, uncompromised cells.

The presence of unlabeled test compound that binds to target kinase results in a loss of BRET signal. As BRET has tight distance constraints, the data obtained is specific for the kinase fused to NanoLuc® luciferase. In addition, the data results in a quantitative intracellular affinity provided the appropriate tracer concentration is used.

NanoBRET TE Kinase Assay enables measurements of kinase inhibitor affinity

Example Kinase Target Engagement Data

Measure Affinity, Selectivity, Potency and Residence Time

Affinity
Selectivity
Potency
Residence Time

Obtain Quantitative Measurement of Compound Intracellular Affinity

Data showing the affinity of various kinase inhibitors for target kinase binding sites
Measuring Affinity of Different Kinase Inhibitor Types. NanoBRET® kinase tracers are based on ATP-competitive kinase inhibitors. Using NanoBRET® TE Kinase Assays, compounds that compete with the ATP binding site (Type I & II) as well as those that modulate the structure of the ATP site via allosteric sites (Type III & IV) have been measured. Top panels show characterization of Type I & II inhibitors at BTK and MET. Bottom panels show characterization of Type I, II, and allosteric (III or IV) inhibitors at Abl and RIPK1 kinases.

Determine Compound Cellular Selectivity and Fractional Occupancy for Related Kinases

Data comparing inhibitor affinity for wild-type and mutant kinases

NanoBRET® Target Engagement can be used to compare inhibitor affinity for wild-type (WT) and mutant kinases. NanoBRET® TE Intracellular Kinase Assay K-10 was used for JAK and JAK(V617F), which is a clinically acquired mutation found in myeloproliferative cancers. Panel A: Engagement of Type I ATP competitive inhibitors against JAK2(V617F). Panel B: Target engagement potency was stronger for Type I inhibitor ruxolitinib with JAK2(V617F) versus JAK2 wild-type. Panel C: This differed from the finding with the Type II inhibitor CHZ-868, which had similar affinity for both JAK2(V617F) mutant and JAK2 wild-type kinases.

Achieve Improved Correlation between Compound Affinity and Downstream Functional Potency

NanoBRET™ Target Engagement Data can Correlate with Cellular Functional Potency.
NanoBRET® Target Engagement Data can Correlate with Cellular Functional Potency. Panel A: Cellular affinities of the multi-kinase inhibitor Crizotinib for a panel of full-length kinases in live cells were obtained using NanoBRET® TE Kinase assays. MET and ALK kinases have been found to be the primary targets of Crizotinib. Panel B: These Crizotinib apparent affinities were used to create a correlation plot using published cellular phospho-ELISA potencies for these same kinases. The results indicate that NanoBRET® TE data can correlate well with cellular functional assay data such as phospho-ELISA. NanoBRET® TE Kinase inhibitor affinities can be predictive of inhibition observed with lower throughput cellular potency assays. For additional study details, see Vasta et al. (2018) Cell Chem Biol. 25(2), 206-214

Assess Compound Residence Time in Live Cells

Kinase inhibitor residence time evaluated in a simple format
Intracellular residence time can be evaluated in a simple format, wherein unmodified compound is added prior to tracer addition. After compound washout, the tracer is added and residence time is quantified in live cells.
Equilibrium binding of kinase inhibitors may not always correlate with binding kinetics
Equilibrium (steady-state) binding may not always correlate with binding kinetics. The first-generation chronic myelogenous leukemia drug Imatinib shows weaker affinity (Panel A) and shorter residence time (Panel B) at Abl, compared to second and third generation drugs (Dasatinib and Ponatinib). The third-generation inhibitor Ponatinib displays similar affinity to the second-generation inhibitor Dasatinib (Panel A), but much more durable binding or longer residence time following washout in live cells (Panel B).

Q & A

NanoBRET™ TE Intracellular Kinase Assay に使用できる細胞種は?

NanoBRET™ TE Intracellular Kinase Assay(#TM598および#TM603)の技術マニュアルではHEK293細胞を使用していますが、HeLaやU2OSなどの細胞タイプでも使用されています。HEK293と異なる細胞タイプを使用する場合は、NanoLuc® 融合ベクター導入する際のトランスフェクション条件について最適化することを推奨します。

ADH (adherent) と NBS (non-binding surface) のアッセイフォーマットの違いは?

新しい付着(ADH)アッセイフォーマットは、オリジナルの非結合表面(NBS)アッセイフォーマットと比較してより効率的です。ADH フォーマットでは、組織培養処理プレートで接着細胞を使用します。 

NBS フォーマットでは、アッセイプレートに移す前日に細胞をプレートまたはディッシュにトランスフェクションする必要があります。アッセイ当日に細胞を採取し、アッセイを実行する前に非結合表面アッセイプレートに播種します。非結合表面プレートは、従来のポリスチレンアッセイプレートでの使用に適さない特定のトレーサーに最適です。

ADH フォーマットでは組織培養処理プレートを使用し、アッセイプレートでキナーゼ - NanoLuc® 融合ベクターをトランスフェクションすることができます。前日にトランスフェクションした細胞をアッセイプレートに播種するため、ADHフォーマットでは回収と播種のステップは不要です。

興味のあるキナーゼの NanoBRET™ TE データはどこで見ることができますか?

使用可能なすべてのキナーゼおよびキナーゼ複合体は、アプリケーションノートおよびデータへのリンクとともにここにリストされています。すでにNBS フォーマットでテストされている場合は、別のアプリケーションノートのリンクが表に付加されています。アプリケーションノートは、個々のキナーゼ- NanoLuc® 融合ベクターの製品ページでもご覧いただけます。

最大のアッセイウィンドウを提供するためにキナーゼごとに推奨されるアッセイ/トレーサーが1つあります。ただし、いくつかのキナーゼには、他のアッセイ法が記載された追加のアプリケーションノートがあります。推奨アッセイ以外の追加データについては、キナーゼ - NanoLuc® 融合ベクターの製品ページで提供されているものもあります。 

ニーズに応じて、最大のウィンドウを持つアッセイは有利な場合があるため推奨されるアッセイとして選択されます。他の場合には、複数のキナーゼに対して同じアッセイ/トレーサーを使用することが望ましい場合があります。この場合、推奨されるアッセイは、研究する各キナーゼで同じではない場合があります。アッセイウィンドウとアッセイ機能のガイドラインについては、#TM598または#TM603を参照してください。

標的とするキナーゼが Kinase Target Engagement Assay Selection Table に無い場合、オリジナルの NanoBRET™ TE Assay を構築するオプションはありますか?

当社のカスタムアッセイサービスでは 追加のキナーゼNanoLuc®融合ベクターとNanoBRET™ TE Kinase Assay を開発し、提供してきました。ご希望のキナーゼアッセイが開発されていない場合にはカスタムチームが開発、あるいはご自身でのアッセイ開発をサポートいたします。こちらからお問い合わせください。

How Can We Help You?

In addition to the pre-built kinase assays featured on this page, we also offer kits and reagent to build your own NanoBRET® Target Engagement assays, and custom assay development capabilities.